{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T13:52:45Z","timestamp":1750859565387},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,12,1]]},"DOI":"10.2169\/internalmedicine.9545-22","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T22:13:30Z","timestamp":1652480010000},"page":"3575-3579","source":"Crossref","is-referenced-by-count":7,"title":["Bing-Neel Syndrome Successfully Treated with Tirabrutinib"],"prefix":"10.2169","volume":"61","author":[{"given":"Takashi","family":"Oyama","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Taoka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Maki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Masamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan"},{"name":"Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Swerdlow SH, Campo E, Harris NL, et al., Eds. World Health Organization, Lyon, 2017: 232-235."},{"key":"2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3324\/haematol.2016.147728","volume":"102","author":"MC Minnema","year":"2017","unstructured":"2. Minnema MC, Kimby E, D&apos;Sa S, et al. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica 102: 43-51, 2017.","journal-title":"Haematologica","ISSN":"http:\/\/id.crossref.org\/issn\/0390-6078","issn-type":"print"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fintelmann F, Forghani R, Schaefer PW, Hochberg EP, Hochberg FH. Bing-Neel Syndrome revisited. Clin Lymphoma Myeloma 9: 104-106, 2009.","DOI":"10.3816\/CLM.2009.n.028"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstr\u00f6m&apos;s macroglobulinemia. N Engl J Med 372: 1430-1440, 2015.","DOI":"10.1056\/NEJMoa1501548"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Liclican A, Serafini L, Xing W, et al. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton&apos;s tyrosine kinase reveals differences in on - and off - target inhibition. Biochim Biophys Acta Gen Subj 1864: 129531, 2020.","DOI":"10.1016\/j.bbagen.2020.129531"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sekiguchi N, Rai S, Munakata W, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO\/GS-4059) in patients with Waldenstr\u00f6m&apos;s macroglobulinemia. Cancer Sci 111: 3327-3337, 2020.","DOI":"10.1111\/cas.14561"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Narita Y, Nagane M, Mishima K, et al. Phase I\/II study of tirabrutinib, a second-generation Bruton&apos;s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro Oncol 23: 122-133, 2021.","DOI":"10.1093\/neuonc\/noaa145"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Saburi M, Saburi Y, Kawano K, Sato R, Urabe S, Ohtsuka E. Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing-Neel syndrome. Int J Hematol 115: 585-589, 2022.","DOI":"10.1007\/s12185-021-03246-z"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Castillo JJ, D&apos;Sa S, Lunn MP, et al. Central nervous system involvement by Waldenstr\u00f6m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol 172: 709-715, 2016.","DOI":"10.1111\/bjh.13883"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Simon L, Fitsiori A, Lemal R, et al. Bing-Neel syndrome, a rare complication of Waldenstr\u00f6m macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO). Haematologica 100: 1587-1594, 2015.","DOI":"10.3324\/haematol.2015.133744"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Poulain S, Boyle EM, Roumier C, et al. <i>MYD88<\/i> L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br J Haematol 167: 506-513, 2014.","DOI":"10.1111\/bjh.13078"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Castillo JJ, Treon SP. How we manage Bing-Neel syndrome. Br J Haematol 187: 277-285, 2019.","DOI":"10.1111\/bjh.16167"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463: 88-92, 2010.","DOI":"10.1038\/nature08638"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstr\u00f6m&apos;s macroglobulinemia. N Engl J Med 367: 826-833, 2012.","DOI":"10.1056\/NEJMoa1200710"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Castillo JJ, Itchaki G, Paludo J, et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood 133: 299-305, 2019.","DOI":"10.1182\/blood-2018-10-879593"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/23\/61_9545-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:30:54Z","timestamp":1715315454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/23\/61_9545-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":15,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9545-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"article-number":"9545-22"}}